Document is current
Any future updates will be listed below
-
Authors
Escribano-Núñez, Ana https://orcid.org/0000-0002-4057-8400
Cornelis, Frederique M. F. https://orcid.org/0000-0002-4144-5861
De Roover, Astrid https://orcid.org/0000-0003-0321-2896
Sermon, An https://orcid.org/0000-0001-6295-9127
Cailotto, Frédéric https://orcid.org/0000-0002-4941-9238
Lories, Rik J. https://orcid.org/0000-0002-5986-3092
Monteagudo, Silvia https://orcid.org/0000-0002-3849-6270
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G059223N, G056822N, 11L1822N, 12AMS24N, G097118N)
- License Information
-
More Information
Article History
Received: 21 March 2024
Accepted: 14 October 2024
First Online: 24 October 2024
Competing interests
: Leuven Research and Development, the technology transfer office of KU Leuven, has received consultancy and speaker fees and research grants on behalf of R.J.L. from Abbvie, Boehringer-Ingelheim, Amgen (formerly Celgene), Eli-Lilly, Galapagos, Janssen, Fresenius Kabi, MSD, Novartis, Pfizer, Biosplice Therapeutics (formerly Samumed), Biocon (formerly Viatris), UCB. None of these are directly related to the work presented here. The other authors declare no competing interests.
